Jan Nilsson, CEO at CombiGene, visited BioStock’s studio to talk about the company’s second quarter. The discussion also covers the collaboration with Zyneyro and the development of new treatments targeting severe chronic pain conditions. We also learn more about a recent meeting with partner Spark Therapeutics, and Nilsson’s stepping down as CEO. Additionally, the interview introduces the new CEO, Peter Ekolind, and explores Nilsson’s future role at CombiGene.
Watch the studio interview with CombiGene’s CEO Jan Nilsson below.The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.